Astrazeneca plc expanded its reach in the global respiratory market with a $575 million deal to acquire the core respiratory assets of Takeda Pharmaceutical Co. Ltd. The transaction included the expansion of rights to roflumilast, marketed as Daliresp in the U.S. and Daxas elsewhere, a once-daily oral PDE4 inhibitor approved to treat chronic obstructive pulmonary disease (COPD).